Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Swiss Cancer Institute
Swiss Cancer Institute
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Beth Israel Deaconess Medical Center
Mayo Clinic
University of Miami
University of Alabama at Birmingham
University of Alabama at Birmingham
National Cancer Institute (NCI)
Technical University of Munich
Northwestern University